Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcin Kowanetz

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 19, 2018
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabBharathi Vennapusa, Brian Baker, Marcin Kowanetz, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
Science Translational Medicine|March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyMaud Mayoux, Andreas Roller, Vesna Pulko, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2010
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytesMarcin Kowanetz, Xiumin Wu, John Lee, et al.
Plos One|May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancerWillemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Nature Medicine|August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R Gandara, Sarah M Paul, Marcin Kowanetz, et al.
Oral Oncology|August 19, 2019
Immune profiles in primary squamous cell carcinoma of the head and neckVassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 19, 2018
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for AtezolizumabBharathi Vennapusa, Brian Baker, Marcin Kowanetz, et al.
The New England Journal of Medicine|June 5, 2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCMark A Socinski, Robert M Jotte, Federico Cappuzzo, et al.
The Lancet. Respiratory Medicine|March 30, 2019
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Tony S K Mok, Makoto Nishio, et al.
Science Translational Medicine|March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyMaud Mayoux, Andreas Roller, Vesna Pulko, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2010
Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytesMarcin Kowanetz, Xiumin Wu, John Lee, et al.
Plos One|May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancerWillemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Nature Medicine|August 8, 2018
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R Gandara, Sarah M Paul, Marcin Kowanetz, et al.
Oral Oncology|August 19, 2019
Immune profiles in primary squamous cell carcinoma of the head and neckVassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 20, 2018
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung CancerLouis Fehrenbacher, Joachim von Pawel, Keunchil Park, et al.
Nature|November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsRoy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
Pageof 5